Who
Lynx1 Capital Management LP
10% owner
Company insider
Files Form 4 as: 10% owner, Korro Bio; 10% owner, Passage Bio; 10% owner, TScan Therapeutics; 10% owner, Neuphoria Therapeutics; 10% owner, Cullinan Therapeutics.
In numbers
- Trades disclosed
- 30
- Buys
- 24
- Sells
- 1
- Bought
- $20.1M
- Sold
- $64K
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 31 May 2023
- Last trade
- 10 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 13 Aug 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Bought | $19K1,462 at $13.19 | filing |
| 10 Aug 2026filed 13 Aug 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Bought | $19K1,462 at $13.19 | filing |
| 6 Aug 2026filed 13 Aug 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Bought | $60K5,222 at $11.40 | filing |
| 6 Aug 2026filed 13 Aug 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Bought | $60K5,222 at $11.40 | filing |
| 25 Jun 2026filed 29 Jun 2026 | PASG Passage BioBiotechnology | SEC FORM 4 Bought | $206K50,055 at $4.12 | filing |
| 31 Mar 2026filed 2 Apr 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Bought | $5,512520 at $10.60 | filing |
| 23 Dec 2025filed 23 Dec 2025 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,6096,232 at $0.90 | filing |
| 22 Dec 2025filed 23 Dec 2025 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Bought | $68K75,500 at $0.90 | filing |
| 19 Dec 2025filed 23 Dec 2025 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Bought | $72K80,069 at $0.90 | filing |
| 21 Oct 2025filed 23 Oct 2025 | NEUP Neuphoria TherapeuticsBiotechnology | SEC FORM 4 Bought | $3.3M639,110 at $5.14 | filing |
| 17 Oct 2025filed 21 Oct 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Bought | $253K32,217 at $7.84 | filing |
| 16 Oct 2025filed 21 Oct 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.3M150,000 at $8.86 | filing |
| 15 Oct 2025filed 21 Oct 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Bought | $409K51,500 at $7.94 | filing |
| 14 Oct 2025filed 21 Oct 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Bought | $114K15,032 at $7.59 | filing |
| 10 Oct 2025filed 10 Oct 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.0M277,298 at $7.36 | filing |
| 9 Oct 2025filed 10 Oct 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Bought | $4.2M626,043 at $6.70 | filing |
| 8 Oct 2025filed 10 Oct 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Bought | $3.6M556,300 at $6.46 | filing |
| 24 Jul 2025filed 24 Jul 2025 | PASG Passage BioBiotechnology | SEC FORM 4 Bought | $379K66,423 at $5.71 | filing |
| 23 Jul 2025filed 24 Jul 2025 | PASG Passage BioBiotechnology | SEC FORM 4 Bought | $283K49,302 at $5.74 | filing |
| 22 Jul 2025filed 24 Jul 2025 | PASG Passage BioBiotechnology | SEC FORM 4 Bought | $71K13,123 at $5.44 | filing |
News
Critical Survey: TScan Therapeutics (NASDAQ:TCRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY)TCRX · dailypolitical.com · 22 Oct 2026AbbVie (NYSE:ABBV) & TScan Therapeutics (NASDAQ:TCRX) Financial ComparisonTCRX · tickerreport.com · 22 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyTCRX · themarketsdaily.com · 20 Oct 2026BioLineRx (NASDAQ:BLRX) and Korro Bio (NASDAQ:KRRO) Head to Head SurveyKRRO · dailypolitical.com · 14 Oct 2026Contrasting BioLineRx (NASDAQ:BLRX) & Korro Bio (NASDAQ:KRRO)KRRO · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Lynx1 Capital Management LP; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.